Emcure Pharmaceuticals Limited has informed the Exchange regarding a press release dated March 02, 2026, titled "Press Release titled Emcure Pharmaceuticals and Roche Sign Distribution Agreement to Strengthen Nephrology and Transplant Care in India ".
EMCURE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.1 pts more than Nifty Smallcap 250 and 3.0 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Emcure Pharmaceuticals has signed a distribution agreement with Swiss pharma major Roche to market select Roche brands in India. The agreement covers three key products: CellCept (an immunosuppressant for organ transplant patients), and Mircera and Neorecormon (treatments for anemia linked to chronic kidney disease). The partnership takes effect from April 1, 2026, and is aimed at expanding patient access to these therapies across India. Emcure is already a market leader in anemia management with a strong presence in nephrology, and says this deal complements its existing portfolio. This is a distribution partnership, not an acquisition or joint venture — Emcure will distribute Roche's established brands using its own network.
Positive for shareholders — adds globally recognized brands to Emcure's portfolio in a therapeutic area where it already leads, potentially boosting revenues and market share in nephrology and transplant care. No equity dilution or major capital outlay involved since this is a distribution arrangement.